Darentin en es it fr

Darentin Brand names, Darentin Analogs

Darentin Brand Names Mixture

  • No information avaliable

Darentin Chemical_Formula


Darentin RX_link


Darentin fda sheet

Darentin msds (material safety sheet)

Darentin MSDS

Darentin Synthesis Reference

No information avaliable

Darentin Molecular Weight

243.163 g/mol

Darentin Melting Point

No information avaliable

Darentin H2O Solubility

Freely soluble

Darentin State


Darentin LogP

No information avaliable

Darentin Dosage Forms

Solution for injection (50mg/mL)

Darentin Indication

For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.

Darentin Pharmacology

Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.

Darentin Absorption

No information avaliable

Darentin side effects and Toxicity

Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.

Darentin Patient Information

Darentin Organisms Affected

Humans and other mammals